Yup. (And great post from Hosai).....I'm wondering if - on their second chance trying to convince the new 35 member CHMP panel 75 days from now - they can somehow introduce this new evidence as coming from the original data the first panel was limited to viewing, According to the rules (I think it was rule number 21) no new data can be presented ... but those other two rival mab drugs on their second chance at review DID manage to squeeze in new interps of old data such that they made their case sufficiently. If we can somehow do something similar and bring in this new cohort and why it works so well, then we might have a chance. Not sure if that cohort was large enough to make them happy. A new trial on just that genetic cohort is something even Anavex might be able to do. So why didn't they two years ago? Shouldn't they have discovered this signal earlier - since as Chat says - it's a gene that plays right in the areas that Sigmar1 plays in.
If ChatGBT can see it so easily than why didn't our scientists see it a long time ago...and test it? Maybe we do need a BP partner to test stuff like these ideas out with our drug so we don't just run trials kind of blind and figure out what MIGHT have happened two years later!!!
Market Data 
Markets 
AI
